Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

iBio Inc.

www.ibioinc.com

Latest From iBio Inc.

CC-Pharming And iBio Expand Chinese Rituximab Venture

A year after their initial tie-up, US plant-based tech firm iBio Inc. and China’s CC-Pharming Ltd are expanding their collaboration on developing a plant-derived bio-better rituximab candidate for the Chinese market.

Deals Biosimilars

Deal Watch: BridgeBio To Launch New Subsidiary Around Rare Disease Candidate Obtained From Alexion

Sanofi completes the transition of its infectious disease unit to Evotec. Perhaps not yet done with virology, Gilead licenses technology for HIV/hep B vaccines from Hookipa.

Deals Business Strategies

Deals Shaping the Medical Industry (2/2012)

The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

Medical Device BioPharmaceutical

Deals Shaping the Medical Industry (12/2010)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Nutraceuticals
    • Vaccines
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Metabolic Disorders
  • Alias(es)
  • iBioPharma Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • iBio Inc.
  • Senior Management
  • Robert B Kay, Chmn. & CEO
    Mark Giannone, CFO
    Terence E Ryan, PhD, CSO
    Douglas C Hicks, VP, Bus. Dev.
    Robert L Irwin, Pres.
  • Contact Info
  • iBio Inc.
    Phone: (302) 355-0650
    9 Innovation Way, Ste. 100
    Newark, DE 19711
    USA
UsernamePublicRestriction

Register